Matthew Lunning, DO, presents the efficacy and safety findings of the L-MIND trial in relapsed/refractory diffuse large B-cell lymphoma and discusses the implications for clinical practice.
Matthew A. Lunning, DO, FACP
Articles by Matthew A. Lunning, DO, FACP
Dr Matthew Lunning reviews second-line treatment options for patients with R/R DLBCL and provides insight on individualizing therapy.
Assessing Risk to Guide First-Line Treatment Selection in DLBCL
Published: | Updated:
DLBCL expert Matthew Lunning, DO, describes risk assessment in patients with DLBCL and how it informs first-line treatment choice.
Case Review of a 71-Year-Old Woman Presenting With DLBCL
Published: | Updated:
Matthew Lunning, DO, presents a case of a 71-year-old woman with relapsed/refractory diffuse large B-cell lymphoma and discusses considerations for therapy.
Matthew Lunning, DO, presents a case study of a 71-year-old woman with relapsed/refractory diffuse large B-cell lymphoma.